Designing and Building Oncolytic Viruses

References

• Breitbach CJ , LichtyBD, BellJC . Oncolytic viruses: therapeutics with an identity crisis . EBioMedicine9, 31 – 36 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengKW, BellJC . Oncolytic virotherapy . Nat. Biotechnol.30 ( 7 ), 658 – 670 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Miest TS , CattaneoR . New viruses for cancer therapy: meeting clinical needs . Nat. Rev. Microbiol.12 ( 1 ), 23 – 34 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kelly E , RussellSJ . History of oncolytic viruses: genesis to genetic engineering . Mol. Ther.15 ( 4 ), 651 – 659 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Cattaneo R , MiestT, ShashkovaEV, BarryMA . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded . Nat. Rev. Microbiol.6 ( 7 ), 529 – 540 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Liu TC , GalanisE, KirnD . Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress . Nat. Clin. Pract. Oncol.4 ( 2 ), 101 – 117 ( 2007 ).
   PubMedGoogle Scholar
• Bell J , McfaddenG . Viruses for tumor therapy . Cell Host Microbe15 ( 3 ), 260 – 265 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Naik S , NaceR, FederspielMJ, BarberGN, PengKW, RussellSJ . Curative one-shot systemic virotherapy in murine myeloma . Leukemia26 ( 8 ), 1870 – 1878 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yu YA , GalanisC, WooYet al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68 . Mol. Cancer Ther.8 ( 1 ), 141 – 151 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Eager RM , NemunaitisJ . Clinical development directions in oncolytic viral therapy . Cancer Gene Ther.18 ( 5 ), 305 – 317 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Russell SJ , FederspielMJ, PengKWet al. Remission of disseminated cancer after systemic oncolytic virotherapy . Mayo Clin. Proc.89 ( 7 ), 926 – 933 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Andtbacka RH , RossM, PuzanovIet al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial . Ann. Surg. Oncol.23 ( 13 ), 4169 – 4177 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Puzanov I , MilhemMM, MinorDet al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma . J. Clin. Oncol.34 ( 22 ), 2619 – 2626 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Verheije MH , LamfersML, WurdingerTet al. Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma . J. Virol.83 ( 15 ), 7507 – 7516 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Wurdinger T , VerheijeMH, RaabenMet al. Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody . Gene Ther.12 ( 18 ), 1394 – 1404 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Van Rikxoort M , MichaelisM, WolschekMet al. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame . PLoS ONE7 ( 5 ), e36506 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kasloff SB , PizzutoMS, Silic-BenussiM, PavoneS, CiminaleV, CapuaI . Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines . J. Virol.88 ( 16 ), 9321 – 9334 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mansour M , PaleseP, ZamarinD . Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells . J. Virol.85 ( 12 ), 6015 – 6023 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Msaouel P , OpyrchalM, Domingo MusibayE, GalanisE . Oncolytic measles virus strains as novel anticancer agents . Expert Opin. Biol. Ther.13 ( 4 ), 483 – 502 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Galanis E , AthertonPJ, MaurerMJet al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer . Cancer Res.75 ( 1 ), 22 – 30 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Csatary LK , MossRW, BeuthJ, TorocsikB, SzeberenyiJ, BakacsT . Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H) . Anticancer Res.19 ( 1B ), 635 – 638 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Asada T . Treatment of human cancer with mumps virus . Cancer34 ( 6 ), 1907 – 1928 ( 1974 ).
   PubMed Web of Science ®Google Scholar
• Ammayappan A , RussellSJ, FederspielMJ . Recombinant mumps virus as a cancer therapeutic agent . Mol. Ther. Oncolytics3, 16019 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hutzen B , RaffelC, StudebakerAW . Advances in the design and development of oncolytic measles viruses . Oncolytic Virother.4, 109 – 118 ( 2015 ).
   PubMedGoogle Scholar
• Ruiz AJ , RussellSJ . MicroRNAs and oncolytic viruses . Curr. Opin. Virol.13, 40 – 48 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Brown MC , DobrikovMI, GromeierM . Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis . J. Virol.88 ( 22 ), 13149 – 13160 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Reddy PS , BurroughsKD, HalesLMet al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers . J. Natl Cancer Inst.99 ( 21 ), 1623 – 1633 ( 2007 ).
   PubMedGoogle Scholar
• Gong J , SachdevE, MitaAC, MitaMM . Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity . World J. Methodol.6 ( 1 ), 25 – 42 ( 2016 ).
   PubMedGoogle Scholar
• Twitty CG , DiagoOR, HoganDJet al. Retroviral replicating vectors deliver cytosine deaminase leading to targeted 5-fluorouracil-mediated cytotoxicity in multiple human cancer types . Hum. Gene Ther. Methods27 ( 1 ), 17 – 31 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF , LandolfiJ, HoganDJet al. Phase I trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma . Sci. Transl. Med.8 ( 341 ), 341ra375 ( 2016 ).
   Web of Science ®Google Scholar
• Logg CR , LoggA, MatusikRJ, BochnerBH, KasaharaN . Tissue-specific transcriptional targeting of a replication-competent retroviral vector . J. Virol.76 ( 24 ), 12783 – 12791 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Tai CK , LoggCR, ParkJM, AndersonWF, PressMF, KasaharaN . Antibody-mediated targeting of replication-competent retroviral vectors . Hum. Gene Ther.14 ( 8 ), 789 – 802 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Zhang L , SteeleMB, JenksNet al. Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFNbeta-NIS . Hum. Gene Ther. Clin. Dev.27 ( 3 ), 111 – 122 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Pol JG , ZhangL, BridleBWet al. Maraba virus as a potent oncolytic vaccine vector . Mol. Ther.22 ( 2 ), 420 – 429 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Muharemagic D , LabibM, GhobadlooSM, ZamayAS, BellJC, BerezovskiMV . Anti-Fab aptamers for shielding virus from neutralizing antibodies . J. Am. Chem. Soc.134 ( 41 ), 17168 – 17177 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bourgeois-Daigneault MC , RoyDG, FallsTet al. Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity . Mol. Ther. Oncolytics3, 16001 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Tesfay MZ , KirkAC, HadacEMet al. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice . J. Virol.87 ( 7 ), 3752 – 3759 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hastie E , GrdzelishviliVZ . Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer . J. Gen. Virol.93 ( Pt 12 ), 2529 – 2545 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Unno Y , ShinoY, KondoFet al. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain . Clin. Cancer Res.11 ( 12 ), 4553 – 4560 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ramachandran M , YuD, DyczynskiMet al. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus . Clin. Cancer Res. doi:10.1158/1078-0432.CCR-16-0925 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Quetglas JI , LabianoS, AznarMAet al. Virotherapy with a semliki forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade . Cancer Immunol. Res.3 ( 5 ), 449 – 454 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Granot T , YamanashiY, MerueloD . Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity . Mol. Ther.22 ( 1 ), 112 – 122 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Alemany R , BalagueC, CurielDT . Replicative adenoviruses for cancer therapy . Nat. Biotechnol.18 ( 7 ), 723 – 727 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Trujillo MA , OnealMJ, McdonoughSJ, MorrisJC . Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy . Gene Ther.20 ( 5 ), 567 – 574 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Grunwald GK , VetterA, KlutzKet al. EGFR-targeted adenovirus dendrimer coating for improved systemic delivery of the theranostic NIS gene . Mol. Ther. Nucleic Acids2, e131 ( 2013 ).
   PubMedGoogle Scholar
• Post DE , SandbergEM, KyleMMet al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4 . Cancer Res.67 ( 14 ), 6872 – 6881 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Choi IK , LeeJS, ZhangSNet al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha . Gene Ther.18 ( 9 ), 898 – 909 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rehman H , SilkAW, KaneMP, KaufmanHL . Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy . J. Immunother. Cancer4, 53 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Cuddington BP , MossmanKL . Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic . Curr. Opin. Virol.13, 11 – 16 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wong RJ , ChanMK, YuZet al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12 . Clin. Cancer Res.10 ( 1 Pt 1 ), 251 – 259 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Friedman GK , BeierleEA, GillespieGYet al. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children . Mol. Ther. Oncolytics2, pii: 15016 ( 2015 ).
   Web of Science ®Google Scholar
• Campadelli-Fiume G , PetrovicB, LeoniVet al. Retargeting strategies for oncolytic herpes simplex viruses . Viruses8 ( 3 ), 63 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mazzacurati L , MarzulliM, ReinhartBet al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV . Mol. Ther.23 ( 1 ), 99 – 107 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Menotti L , NicolettiG, GattaVet al. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells . Proc. Natl Acad. Sci. USA106 ( 22 ), 9039 – 9044 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Marchini A , BonifatiS, ScottEM, AngelovaAL, RommelaereJ . Oncolytic parvoviruses: from basic virology to clinical applications . Virol. J.12, 6 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Haag A , MentenP, Van DammeJ, DinsartC, RommelaereJ, CornelisJJ . Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice . Hum. Gene Ther.11 ( 4 ), 597 – 609 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Chan WM , McfaddenG . Oncolytic poxviruses . Annu. Rev. Virol.1 ( 1 ), 119 – 141 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Flint SJ , RacanielloVR, RallGF, SkalkaAM, EnquistLW . Principles of Virology (4th Edition) . ASM Press, Washington, DC, USA ( 2015 ).
   Google Scholar
• Wagner EK , WagnerEK . Basic Virology (3rd Edition) . Blackwell Publishing, MA, USA ( 2008 ).
   Google Scholar
• Bailey K , KirkA, NaikSet al. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters . PLoS ONE8 ( 9 ), e73759 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Miller A , SuksanpaisanL, NaikSet al. Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy . Mol. Ther. Oncolytics1, 14005 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Breitbach CJ , BurkeJ, JonkerDet al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans . Nature477 ( 7362 ), 99 – 102 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Manickan E , SmithJS, TianJet al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors . Mol. Ther.13 ( 1 ), 108 – 117 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengKW . Viruses as anticancer drugs . Trends Pharmacol. Sci.28 ( 7 ), 326 – 333 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Miller AC , RussellSJ . Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors . Virus Adapt. Treat.6, 11 – 31 ( 2014 ).
   Google Scholar
• Miller A , NaceR, Ayala-BretonCCet al. Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses . Mol. Ther.24 ( 2 ), 306 – 317 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Fang J , NakamuraH, MaedaH . The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect . Adv. Drug Deliv. Rev.63 ( 3 ), 136 – 151 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hallak LK , MerchanJR, StorgardCM, LoftusJC, RussellSJ . Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression . Cancer Res.65 ( 12 ), 5292 – 5300 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Jing Y , TongC, ZhangJet al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor . Cancer Res.69 ( 4 ), 1459 – 1468 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Breitbach CJ , De SilvaNS, FallsTJet al. Targeting tumor vasculature with an oncolytic virus . Mol. Ther.19 ( 5 ), 886 – 894 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Myers R , CovielloC, ErbsPet al. Polymeric cups for cavitation-mediated delivery of oncolytic vaccinia virus . Mol. Ther.4 ( 9 ), 1627 – 1633 ( 2016 ).
   Google Scholar
• Nande R , HowardCM, ClaudioPP . Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art . Oncolytic Virother.4, 193 – 205 ( 2015 ).
   PubMedGoogle Scholar
• Kaufman HL , AmatrudaT, ReidTet al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional Phase II study . J. Immunother. Cancer4, 12 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ott PA , HodiFS . Talimogene laherparepvec for the treatment of advanced melanoma . Clin. Cancer Res.22 ( 13 ), 3127 – 3131 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Sauthoff H , HuJ, MacaCet al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points . Hum. Gene Ther.14 ( 5 ), 425 – 433 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Liu CS , RussellSJ, PengKW . Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers . Mol. Ther.18 ( 6 ), 1155 – 1164 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tesfay MZ , AmmayappanA, FederspielMJet al. Vesiculovirus neutralization by natural IgM and complement . J. Virol.88 ( 11 ), 6148 – 6157 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Guo ZS , ParimiV, O’malleyMEet al. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host . Gene Ther.17 ( 12 ), 1465 – 1475 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lang SI , GieseNA, RommelaereJ, DinsartC, CornelisJJ . Humoral immune responses against minute virus of mice vectors . J. Gene Med.8 ( 9 ), 1141 – 1150 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Sun JY , Anand-JawaV, ChatterjeeS, WongKK . Immune responses to adeno-associated virus and its recombinant vectors . Gene Ther.10 ( 11 ), 964 – 976 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Peng KW , MyersR, GreensladeAet al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses . Gene Ther.20 ( 3 ), 255 – 261 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bangari DS , MittalSK . Current strategies and future directions for eluding adenoviral vector immunity . Curr. Gene Ther.6 ( 2 ), 215 – 226 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Miest TS , YaiwKC, FrenzkeMet al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis . Mol. Ther.19 ( 10 ), 1813 – 1820 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lech PJ , TobinGJ, BushnellRet al. Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies . PLoS ONE8 ( 1 ), e52306 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lech PJ , PappoeR, NakamuraT, TobinGJ, NaraPL, RussellSJ . Antibody neutralization of retargeted measles viruses . Virology454–455, 237 – 246 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shashkova EV , DoroninK, SenacJS, BarryMA . Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus . Cancer Res.68 ( 14 ), 5896 – 5904 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Koski A , RajeckiM, GuseKet al. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells . J. Gene Med.11 ( 11 ), 966 – 977 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Liu YP , TongC, DispenzieriA, FederspielMJ, RussellSJ, PengKW . Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus . Cancer Gene Ther.19 ( 3 ), 202 – 211 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Laurenzana A , MargheriF, ChillaAet al. Endothelial progenitor cells as shuttle of anticancer agents . Hum. Gene Ther. doi:10.1089/hum.2016.066 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengKW . The utility of cells as vehicles for oncolytic virus therapies . Curr. Opin. Mol. Ther.10 ( 4 ), 380 – 386 ( 2008 ).
   PubMedGoogle Scholar
• Mader EK , MaeyamaY, LinYet al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model . Clin. Cancer Res.15 ( 23 ), 7246 – 7255 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Thorne SH , ContagCH . Combining immune cell and viral therapy for the treatment of cancer . Cell. Mol. Life Sci.64 ( 12 ), 1449 – 1451 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bluming AZ , ZieglerJL . Regression of Burkitt’s lymphoma in association with measles infection . Lancet2 ( 7715 ), 105 – 106 ( 1971 ).
   PubMed Web of Science ®Google Scholar
• Klimstra WB , RymanKD, JohnstonRE . Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor . J. Virol.72 ( 9 ), 7357 – 7366 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Ong HT , TimmMM, GreippPRet al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells . Exp. Hematol.34 ( 6 ), 713 – 720 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Schneider U , BulloughF, VongpunsawadS, RussellSJ, CattaneoR . Recombinant measles viruses efficiently entering cells through targeted receptors . J. Virol.74 ( 21 ), 9928 – 9936 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Nakamura T , PengKW, HarveyMet al. Rescue and propagation of fully retargeted oncolytic measles viruses . Nat. Biotechnol.23 ( 2 ), 209 – 214 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Verheije MH , RottierPJ . Retargeting of viruses to generate oncolytic agents . Adv. Virol.2012, 798526 ( 2012 ).
   PubMedGoogle Scholar
• Van Den Wollenberg DJ , Van Den HengelSK, DautzenbergIJ, CramerSJ, KranenburgO, HoebenRC . A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting . Gene Ther.15 ( 24 ), 1567 – 1578 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ammayappan A , PengKW, RussellSJ . Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands . J. Virol.87 ( 24 ), 13543 – 13555 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Okazaki K . Proteolytic cleavage of glycoprotein B is dispensable for in vitro replication, but required for syncytium formation of pseudorabies virus . J. Gen. Virol.88 ( Pt 7 ), 1859 – 1865 ( 2007 ).
   PubMedGoogle Scholar
• Springfeld C , Von MesslingV, FrenzkeM, UngerechtsG, BuchholzCJ, CattaneoR . Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases . Cancer Res.66 ( 15 ), 7694 – 7700 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Morodomi Y , YanoT, KinohHet al. BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression . Mol. Ther.20 ( 4 ), 769 – 777 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Alain T , KimTS, LunXet al. Proteolytic disassembly is a critical determinant for reovirus oncolysis . Mol. Ther.15 ( 8 ), 1512 – 1521 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Garcia MA , MeursEF, EstebanM . The dsRNA protein kinase PKR: virus and cell control . Biochimie89 ( 6–7 ), 799 – 811 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Seth RB , SunL, ChenZJ . Antiviral innate immunity pathways . Cell Res.16 ( 2 ), 141 – 147 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Barber GN . Host defense, viruses and apoptosis . Cell Death Differ.8 ( 2 ), 113 – 126 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Thomson BJ . Viruses and apoptosis . Int. J. Exp. Pathol.82 ( 2 ), 65 – 76 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Ahmed M , MckenzieMO, PuckettS, HojnackiM, PoliquinL, LylesDS . Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis . J. Virol.77 ( 8 ), 4646 – 4657 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Chou J , KernER, WhitleyRJ, RoizmanB . Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture . Science250 ( 4985 ), 1262 – 1266 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• He B , GrossM, RoizmanB . The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase . Proc. Natl Acad. Sci. USA94 ( 3 ), 843 – 848 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Bischoff JR , KirnDH, WilliamsAet al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells . Science274 ( 5286 ), 373 – 376 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Buller RM , SmithGL, CremerK, NotkinsAL, MossB . Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype . Nature317 ( 6040 ), 813 – 815 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Tenser RB . Role of herpes simplex virus thymidine kinase expression in viral pathogenesis and latency . Intervirology32 ( 2 ), 76 – 92 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Martuza RL . Conditionally replicating herpes vectors for cancer therapy . J. Clin. Invest.105 ( 7 ), 841 – 846 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Kim JH , OhJY, ParkBHet al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF . Mol. Ther.14 ( 3 ), 361 – 370 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Dalba C , KlatzmannD, LoggCR, KasaharaN . Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors . Curr. Gene Ther.5 ( 6 ), 655 – 667 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Roe T , ReynoldsTC, YuG, BrownPO . Integration of murine leukemia virus DNA depends on mitosis . EMBO J.12 ( 5 ), 2099 – 2108 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Kelly EJ , HadacEM, CullenBR, RussellSJ . MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference . PLoS Pathog.6 ( 3 ), e1000820 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wein LM , WuJT, KirnDH . Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery . Cancer Res.63 ( 6 ), 1317 – 1324 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Sattentau Q . Avoiding the void: cell-to-cell spread of human viruses . Nat. Rev. Microbiol.6 ( 11 ), 815 – 826 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bateman AR , HarringtonKJ, KottkeTet al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells . Cancer Res.62 ( 22 ), 6566 – 6578 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Fu X , TaoL, JinA, VileR, BrennerMK, ZhangX . Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect . Mol. Ther.7 ( 6 ), 748 – 754 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ayala-Breton C , RussellLO, RussellSJ, PengKW . Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus . J. Virol.88 ( 15 ), 8332 – 8339 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• De Wever O , MareelM . Role of tissue stroma in cancer cell invasion . J. Pathol.200 ( 4 ), 429 – 447 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Choi IK , StraussR, RichterM, YunCO, LieberA . Strategies to increase drug penetration in solid tumors . Front. Oncol.3, 193 ( 2013 ).
   PubMedGoogle Scholar
• Yun CO . Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy . Curr. Opin. Mol. Ther.10 ( 4 ), 356 – 361 ( 2008 ).
   PubMedGoogle Scholar
• Kim JH , LeeYS, KimH, HuangJH, YoonAR, YunCO . Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy . J. Natl Cancer Inst.98 ( 20 ), 1482 – 1493 ( 2006 ).
   PubMedGoogle Scholar
• Ganesh S , Gonzalez-EdickM, GibbonsD, Van RoeyM, JoossK . Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models . Clin. Cancer Res.14 ( 12 ), 3933 – 3941 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Guedan S , RojasJJ, GrosA, MercadeE, CascalloM, AlemanyR . Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth . Mol. Ther.18 ( 7 ), 1275 – 1283 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Todd S , TownerJS, SemlerBL . Translation and replication properties of the human rhinovirus genome in vivo and in vitro . Virology229 ( 1 ), 90 – 97 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Lim KI , LangT, LamV, YinJ . Model-based design of growth-attenuated viruses . PLoS Comput. Biol.2 ( 9 ), e116 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hiley CT , YuanM, LemoineNR, WangY . Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours . Gene Ther.17 ( 2 ), 281 – 287 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Laborda E , Puig-SausC, CascalloM, ChillonM, AlemanyR . Adeno-associated virus enhances wild-type and oncolytic adenovirus spread . Hum. Gene Ther. Methods24 ( 6 ), 372 – 380 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yuan Y , AllenLJ . Stochastic models for virus and immune system dynamics . Math. Biosci.234 ( 2 ), 84 – 94 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ , KreitmanR, WilsonW, SquiresD, PastanI . Recombinant immunotoxins for treating cancer . Int. J. Med. Microbiol.293 ( 7–8 ), 577 – 582 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ , WayneAS, KreitmanRJ, PastanI . Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates . Cancer Res.71 ( 20 ), 6300 – 6309 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ladd B , O’KonekJJ, OstruszkaLJ, ShewachDS . Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir . Cancer Gene Ther.18 ( 10 ), 751 – 759 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mesnil M , PiccoliC, TirabyG, WilleckeK, YamasakiH . Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins . Proc. Natl Acad. Sci. USA93 ( 5 ), 1831 – 1835 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Huber BE , AustinEA, RichardsCA, DavisST, GoodSS . Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor-cells transduced with the cytosine deaminase gene – significant antitumor effects when only a small percentage of tumor-cells express cytosine deaminase . Proc. Natl Acad. Sci. USA91 ( 17 ), 8302 – 8306 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Kaufmann JK , ChioccaEA . Glioma virus therapies between bench and bedside . Neuro-Oncol.16 ( 3 ), 334 – 351 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Yurttas C , BerchtoldS, MalekNP, BitzerM, LauerUM . Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene . Hum. Gene Ther. Clin. Dev.25 ( 2 ), 85 – 96 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA , OhwadaA, PascalWR, RussiTJ, CrystalRG . In-vivo adenovirus-mediated gene-transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine . Hum. Gene Ther.6 ( 8 ), 1055 – 1063 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Kasai K , NakashimaH, LiuFet al. Toxicology and biodistribution studies for MGH2.1, an oncolytic virus that expresses two prodrug-activating genes, in combination with prodrugs . Mol. Ther. Nucleic Acids2, e113 ( 2013 ).
   PubMedGoogle Scholar
• Ungerechts G , SpringfeldC, FrenzkeMEet al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus . Mol. Ther.15 ( 11 ), 1991 – 1997 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dadachova E , CarrascoN . The Na+/I- symporter (NIS): imaging and therapeutic applications . Semin. Nucl. Med.34 ( 1 ), 23 – 31 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Miller A , RussellSJ . The use of the NIS reporter gene for optimizing oncolytic virotherapy . Expert Opin. Biol. Ther.16 ( 1 ), 15 – 32 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Dingli D , PengKW, HarveyMEet al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter . Blood103 ( 5 ), 1641 – 1646 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Barton KN , StrickerH, BrownSLet al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate . Mol. Ther.16 ( 10 ), 1761 – 1769 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Podbilewicz B . Virus and cell fusion mechanisms . Annu. Rev. Cell. Dev. Biol.30, 111 – 139 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chang A , DutchRE . Paramyxovirus fusion and entry: multiple paths to a common end . Viruses4 ( 4 ), 613 – 636 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Higuchi H , BronkSF, BatemanA, HarringtonK, VileRG, GoresGJ . Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy . Cancer Res.60 ( 22 ), 6396 – 6402 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Shin EJ , ChangJI, ChoiBet al. Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas . Otolaryngol. Head Neck Surg.136 ( 5 ), 811 – 817 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Diaz RM , BatemanA, EmiliusenLet al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy . Gene Ther.7 ( 19 ), 1656 – 1663 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Guedan S , GrasesD, RojasJJet al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution . Gene Ther.19 ( 11 ), 1048 – 1057 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Simpson GR , CoffinRS . Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control . Methods Mol. Biol.542, 551 – 564 ( 2009 ).
   PubMedGoogle Scholar
• Hanahan D , WeinbergRA . Hallmarks of cancer: the next generation . Cell144 ( 5 ), 646 – 674 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rabinovich GA , GabrilovichD, SotomayorEM . Immunosuppressive strategies that are mediated by tumor cells . Annu. Rev. Immunol.25, 267 – 296 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy . Nat. Rev. Cancer12 ( 4 ), 252 – 264 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Engeland CE , GrossardtC, VeinaldeRet al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy . Mol. Ther.22 ( 11 ), 1949 – 1959 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB , DonlinLT . Regulation of type I interferon responses . Nat. Rev. Immunol.14 ( 1 ), 36 – 49 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Moehler MH , ZeidlerM, WilsbergVet al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells . Hum. Gene Ther.16 ( 8 ), 996 – 1005 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Guo ZS , LiuZ, BartlettDL . Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity . Front. Oncol.4, 74 ( 2014 ).
   PubMedGoogle Scholar
• Shen WW , PatnaikMM, RuizA, RussellSJ, PengKW . Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia . Blood127 ( 11 ), 1449 – 1458 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lichty BD , BreitbachCJ, StojdlDF, BellJC . Going viral with cancer immunotherapy . Nat. Rev. Cancer14 ( 8 ), 559 – 567 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Patel MR , KratzkeRA . Oncolytic virus therapy for cancer: the first wave of translational clinical trials . Transl. Res.161 ( 4 ), 355 – 364 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Buijs PR , VerhagenJH, Van EijckCH, Van Den HoogenBG . Oncolytic viruses: from bench to bedside with a focus on safety . Hum. Vaccin. Immunother.11 ( 7 ), 1573 – 1584 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pol J , BuqueA, ArandaFet al. Trial Watch – oncolytic viruses and cancer therapy . Oncoimmunology5 ( 2 ), e1117740 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lawler SE , SperanzaMC, ChoCF, ChioccaEA . Oncolytic viruses in cancer treatment: a review . JAMA Oncol. doi:10.1001/jamaoncol.2016.2064 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Southam CM , MooreAE . Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus . Cancer5 ( 5 ), 1025 – 1034 ( 1952 ).
   PubMed Web of Science ®Google Scholar
• Hoster HA , ZanesRPJr, Von HaamE . Studies in Hodgkin’s syndrome; the association of viral hepatitis and Hodgkin’s disease; a preliminary report . Cancer Res.9 ( 8 ), 473 – 480 ( 1949 ).
   PubMed Web of Science ®Google Scholar
• Lancaster KZ , PfeifferJK . Viral population dynamics and virulence thresholds . Curr. Opin. Microbiol.15 ( 4 ), 525 – 530 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Korboukh VK , LeeCA, AcevedoAet al. RNA virus population diversity, an optimum for maximal fitness and virulence . J. Biol. Chem.289 ( 43 ), 29531 – 29544 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Andino R , DomingoE . Viral quasispecies . Virology479–480, 46 – 51 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Holland J , SpindlerK, HorodyskiF, GrabauE, NicholS, VandepolS . Rapid evolution of RNA genomes . Science215 ( 4540 ), 1577 – 1585 ( 1982 ).
   PubMed Web of Science ®Google Scholar
• Pfeiffer JK , KirkegaardK . Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice . PLoS Pathog.1 ( 2 ), e11 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Griffin DE , PanCH . Measles: old vaccines, new vaccines . Curr. Top. Microbiol. Immunol.330, 191 – 212 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Agut H , KeanKM, BellocqC, FichotO, GirardM . Intratypic recombination of polioviruses: evidence for multiple crossing-over sites on the viral genome . J. Virol.61 ( 5 ), 1722 – 1725 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Yang CF , ChenHY, JorbaJet al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient . J. Virol.79 ( 20 ), 12623 – 12634 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hampson AW , MackenzieJS . The influenza viruses . Med. J. Aust.185 ( Suppl. 10 ), S39 – S43 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Bergmann M , RomirerI, SachetMet al. A genetically engineered influenza A virus with ras-dependent oncolytic properties . Cancer Res.61 ( 22 ), 8188 – 8193 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Peters C , RabkinSD . Designing herpes viruses as oncolytics . Mol. Ther. Oncolytics2, pii:15010 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Razonable RR . Antiviral drugs for viruses other than human immunodeficiency virus . Mayo Clin. Proc.86 ( 10 ), 1009 – 1026 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ji X , ZhangJ, ChengLet al. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model . Exp. Eye Res.89 ( 2 ), 193 – 199 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zhou X , BrennerMK . Improving the safety of T-cell therapies using an inducible caspase-9 gene . Exp. Hematol.44 ( 11 ), 1013 – 1019 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Zhou X , NaikS, DakhovaO, DottiG, HeslopHE, BrennerMK . Serial activation of the inducible caspase 9 safety switch after human stem cell transplantation . Mol. Ther.24 ( 4 ), 823 – 831 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Abate-Daga D , AndreuN, Camacho-SanchezJet al. Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing . PLoS ONE6 ( 10 ), e26142 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Willmon CL , SalouraV, FridlenderZGet al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma . Cancer Res.69 ( 19 ), 7713 – 7720 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Stojdl DF , LichtyBD, TenoeverBRet al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents . Cancer Cell4 ( 4 ), 263 – 275 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Vile R , AndoD, KirnD . The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider . Cancer Gene Ther.9 ( 12 ), 1062 – 1067 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Aghi M , MartuzaRL . Oncolytic viral therapies – the clinical experience . Oncogene24 ( 52 ), 7802 – 7816 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Frenzke M , SawatskyB, WongXXet al. Nectin-4-dependent measles virus spread to the cynomolgus monkey tracheal epithelium: role of infected immune cells infiltrating the lamina propria . J. Virol.87 ( 5 ), 2526 – 2534 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ludlow M , LemonK, De VriesRDet al. Measles virus infection of epithelial cells in the macaque upper respiratory tract is mediated by subepithelial immune cells . J. Virol.87 ( 7 ), 4033 – 4042 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Leonard VH , SinnPL, HodgeGet al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed . J. Clin. Invest.118 ( 7 ), 2448 – 2458 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Baldo A , GalanisE, TangyF, HermanP . Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination . Hum. Vaccin. Immunother.12 ( 5 ), 1102 – 1116 ( 2016 ).
   PubMed Web of Science ®Google Scholar